Glenmark Pharmaceuticals enters into exclusive agreement with SCD

22 Feb 2018 Evaluate

Glenmark Pharmaceuticals has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the US and Canada. Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize the products in North America.

It is expected that Glenmark will file six Abbreviated New Drug Applications (ANDAs) beginning in the first half of 2019 for the licensed SCD ophthalmic products. According to IMS sales figures, the US brand sales for the six products was approximately $1.7 billion for calendar year 2017.

Glenmark Pharmaceuticals (GPL) is a global innovative pharmaceutical company with operations in more than 50 countries.


Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×